title: Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
abstract: BACKGROUND
  Type III hyperlipoproteinemia is characterized by the accumulation of chylomicron and very low density lipoprotein (VLDL) remnants. Individuals with this disorder have a high risk of premature atherosclerosis, and hypolipidemic drugs are useful in their management.
  
  
  METHODS
  We compared, in a double-blind, placebo-controlled, randomized crossed study, the effects of gemfibrozil (1200 mg/day) and simvastatin (20 mg/day) on lipids, apolipoprotein AI, apolipoprotein B, and apolipoprotein E and on lipids and apolipoprotein B content in VLDL, intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) in 10 patients with type III hyperlipoproteinemia.
  
  
  RESULTS
  Levels of total cholesterol, VLDL cholesterol, IDL cholesterol, and apolipoprotein B decreased with both drugs. Larger reductions in triglycerides (109 +/- 28.2 mg/dL, P =.005), VLDL cholesterol (24.7 +/- 10.9 mg/dL, P =.05), and VLDL triglycerides (86.3 +/- 20.2 mg/dL, P =.003) were obtained with gemfibrozil compared with simvastatin. LDL cholesterol reduction was more effective with simvastatin than with gemfibrozil (44.3 +/- 17.1 mg/dL, P =.03). HDL cholesterol after gemfibrozil was 5.71 +/- 2.37 mg/dL higher than after simvastatin.
  
  
  CONCLUSIONS
  In patients with type III hyperlipoproteinemia gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.
authors.affiliation: Hospital Miguel Servet, Zaragoza, Spain. civeira@posta.unizar.es
authors.forename: F
authors.initials: F
authors.lastname: Civeira
authors.forename: A
authors.initials: A
authors.lastname: Cenarro
authors.forename: J
authors.initials: J
authors.lastname: Ferrando
authors.forename: J
authors.initials: J
authors.lastname: Puzo
authors.forename: A L
authors.initials: AL
authors.lastname: Garcia-Otín
authors.forename: P
authors.initials: P
authors.lastname: Mozas
authors.forename: M
authors.initials: M
authors.lastname: Pocoví
mesh_terms: D000328:Adult; D001053:Apolipoproteins / Q000097:blood*; D004311:Double-Blind Method; D005260:Female; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D019821:Simvastatin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001053:Apolipoproteins; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D019821:Simvastatin; D015248:Gemfibrozil